newsfilter
← Latest News
Business Wire·

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001) Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the